Previous Close | 3.6200 |
Open | 3.7100 |
Bid | 3.4000 x 900 |
Ask | 4.0000 x 900 |
Day's Range | 3.5339 - 3.7300 |
52 Week Range | 2.1600 - 19.8000 |
Volume | |
Avg. Volume | 102,574 |
Market Cap | 238.189M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2250 |
Earnings Date | Sept 09, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.00 |
SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT).
Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance ReaffirmedBOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, representing year-over-year revenue growth of 21%Constant currency revenue growth excluding COVID-19-related revenu
The big shareholder groups in SOPHiA GENETICS SA ( NASDAQ:SOPH ) have power over the company. Insiders often own a...